公开(公告)号：US20070270505A1

公开(公告)日：2007-11-22

申请号：US10587052

申请日：2005-01-24

申请人： Paul Bunn Jr. ,  Christopher Coldren ,  Wilbur Franklin ,  Mark Geraci ,  Barbara Helfrich ,  Fred Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir Witta

发明人： Paul Bunn Jr. ,  Christopher Coldren ,  Wilbur Franklin ,  Mark Geraci ,  Barbara Helfrich ,  Fred Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir Witta

IPC分类号： A61K31/00 ,  A61P35/00 ,  C12Q1/02 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

摘要翻译： 公开了鉴定，提供和使用一组生物标志物，其预测对吉非替尼和其他EGFR抑制剂的敏感性或抗性，以及与之相关的产品和过程。 具体地说，描述了一种用于选择预期从治疗性施用EGFR抑制剂，其激动剂或具有与EGFR抑制剂具有实质上相似的生物学活性的药物中受益的癌症患者的方法。 还描述了鉴定与EGFR途径相互作用以允许或增强对EGFR抑制剂的反应性的分子的方法，以及用于检测指示EGFR抑制剂的敏感性或抗性的基因表达的多种多核苷酸或抗体 ，其激动剂，或具有与EGFR抑制剂基本相似的生物学活性的药物。 还描述了鉴定具有增强EGFR抑制剂功效潜力的化合物的方法。

公开(公告)号：US20100196366A1

公开(公告)日：2010-08-05

申请号：US12670052

申请日：2008-07-23

申请人： Paul A. Bunn ,  Christopher D. Coldren ,  Wilbur A. Franklin ,  Mark W. Geraci ,  Barbara A. Helfrich ,  Fred R. Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir E. Witta

发明人： Paul A. Bunn ,  Christopher D. Coldren ,  Wilbur A. Franklin ,  Mark W. Geraci ,  Barbara A. Helfrich ,  Fred R. Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir E. Witta

IPC分类号： A61K39/395 ,  C12Q1/68 ,  A61K31/5377 ,  A61K31/517 ,  A61K31/497

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

摘要翻译： 公开了鉴定，提供和使用一组预测对EGFR抑制剂的敏感性或抗性的生物标志物，以及与之相关的产品和方法。 在一个实施方案中，描述了一种用于选择预期从治疗性施用EGFR抑制剂，其激动剂或具有与EGFR抑制剂具有实质上相似的生物学活性的药物中受益的癌症患者的方法。 还描述了鉴定与EGFR途径相互作用以允许或增强对EGFR抑制剂的反应性的分子的方法，以及用于检测指示EGFR抑制剂的敏感性或抗性的基因表达的多个多核苷酸或抗体， 其激动剂，或具有与EGFR抑制剂基本相似的生物学活性的药物。 还描述了鉴定具有增强EGFR抑制剂功效潜力的化合物的方法。

公开(公告)号：US08017321B2

公开(公告)日：2011-09-13

申请号：US10587052

申请日：2005-01-24

申请人： Paul A. Bunn, Jr. ,  Christopher D. Coldren ,  Wilbur A. Franklin ,  Mark W. Geraci ,  Barbara A. Helfrich ,  Fred R. Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir E. Witta

发明人： Paul A. Bunn, Jr. ,  Christopher D. Coldren ,  Wilbur A. Franklin ,  Mark W. Geraci ,  Barbara A. Helfrich ,  Fred R. Hirsch ,  Razvan Lapadat ,  Michio Sugita ,  Samir E. Witta

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.

摘要翻译： 公开了鉴定，提供和使用一组生物标志物，其预测对吉非替尼和其他EGFR抑制剂的敏感性或抗性，以及与之相关的产品和过程。 具体地说，描述了一种用于选择预期从治疗性施用EGFR抑制剂，其激动剂或具有与EGFR抑制剂具有实质上相似的生物学活性的药物中受益的癌症患者的方法。 还描述了鉴定与EGFR途径相互作用以允许或增强对EGFR抑制剂的反应性的分子的方法，以及用于检测指示EGFR抑制剂的敏感性或抗性的基因表达的多种多核苷酸或抗体 ，其激动剂，或具有与EGFR抑制剂基本相似的生物学活性的药物。 还描述了鉴定具有增强EGFR抑制剂功效潜力的化合物的方法。